@article{LeyhEhmerRoessleretal.2022,
  author    = {Leyh, Catherine and Ehmer, Ursula and Roessler, Daniel and Philipp, Alexander B. and Reiter, Florian P. and Jeliazkova, Petia and Jochheim, Leonie S. and Jeschke, Matthias and Hammig, Janina and Ludwig, Johannes M. and Theysohn, Jens M. and Geier, Andreas and Lange, Christian M.},
  title     = {Sorafenib versus lenvatinib-based sequential systemic therapy for advanced hepatocellular carcinoma: a real-world analysis},
  series = {Cancers},
  volume    = {14},
  journal   = {Cancers},
  number    = {8},
  issn      = {2072-6694},
  doi       = {10.3390/cancers14081975},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-270765},
  year      = {2022},
  abstract  = {The optimal treatment sequence of tyrosine kinase inhibitor (TKI)-based therapy in patients with hepatocellular carcinoma (HCC) remains unclear. Therefore, sequential systemic therapy after first-line therapy with sorafenib or lenvatinib was compared in a retrospective real-world cohort. In total, 164 patients with HCC were included. Child B cirrhosis was present in 26 patients (16.5\%), whereas 132 patients (83.5\%) had preserved liver function. In total, 72 patients (44\%) discontinued systemic therapy after first-line therapy while 51 (31\%) and 31 (19\%) patients received 2 or more treatment lines. Most notably, median overall survival (mOS) was influenced by liver functional status and patient performance status at the beginning of first-line therapy. Patients receiving a sequential therapy regimen had significantly longer mOS compared to patients that discontinued systemic therapy after omitting first-line treatment. The choice of the initial TKI did not impact mOS. A clear deterioration of liver function could be observed during the course of TKI-based treatment.},
  language  = {en}
}
@article{BaurRitterGermeretal.2016,
  author    = {Baur, Johannes and Ritter, Christian O. and Germer, Christoph-Thomas and Klein, Ingo and Kickuth, Ralph and Steger, Ulrich},
  title     = {Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma},
  series = {Hepatic Medicine},
  volume    = {2016},
  journal   = {Hepatic Medicine},
  number    = {8},
  doi       = {10.2147/HMER.S105395},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-146553},
  pages     = {69-74},
  year      = {2016},
  abstract  = {Purpose: In hepatocellular carcinoma patients with large or multinodal tumors, where curative treatment options are not feasible, transarterial therapies play a major role. Transarterial chemoembolization (TACE) with drug-eluting beads (DEB-TACE) is a promising new approach due to higher intratumoral and lower systemic concentration of the chemotherapeutic agent compared to conventional TACE (cTACE). Patients and methods: In a retrospective analysis, 32 patients with hepatocellular carcinoma who received either DEB or a cTACE were compared regarding survival time, disease recurrence, and side effects such as pain and fever. Results: No significant differences could be detected between the cTACE and DEB-TACE groups with regard to mean hospital stay, appearance of postinterventional fever, or 30-day mortality. However, the application of intravenous analgesics as postinterventional pain medication was needed more often in patients treated with DEB-TACE (57.1\% vs 12.5\%, P=0.0281). The overall median survival after the initial procedure was 10.8 months in the cTACE group and 9.2 months in the DEB-TACE group, showing no significant difference. Conclusion: No survival benefit for patients treated with either DEB-TACE or cTACE was observed. Surprisingly, a higher rate of postinterventional pain could be detected after DEB-TACE.},
  language  = {en}
}